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Introduction. Family member with IBD is the greatest risk factor for developing the disease. The hematological proﬁle of ﬁrst-
degree relatives (FDRs) of Crohn’s disease (CD) patients was studied in order to identify healthy FDRs at risk to develop disease.
Materials and methods. Thirty CD patients, 90 FDRs, and 28 non-related individuals (controls) were enrolled. Hematological
proﬁle and C-reactive protein were determined. Results. All hematological parameters were signiﬁcantly diﬀerent in CD patients
compared to controls, with signiﬁcantly higher levels of CRP, WBC, PMN, MONO, and PLT and lower Hb and lymphocyte count.
The hematological proﬁle of FDRs showed values between the controls and CD patients with ten FDRs that their parameters
matched those of CD patients and signiﬁcantly diﬀerent from other FDRs. This group was deﬁned as high-risk relatives (HRRs).
Conclusions. Analysis of the hematological proﬁle and CRP level might be proven as a fast, reliable, and less money-consuming
tool to identify FDRs with a probable increased risk to develop the disease.
Copyright © 2006 Broide Efrat et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
Familial aggregation of inﬂammatory bowel disease (IBD)
was recognized almost four decades ago [1]. The prevalence
ofIBDinﬁrst-degreerelativesis13.4%–36%[2,3].Thereisa
10–13-fold increase in the familial risk of IBD in ﬁrst-degree
relatives of patients with ulcerative colitis (UC) or Crohn’s
disease(CD)[4].Thegreatestriskfactorforthedevelopment
of IBD is having an aﬀected family member with this disease.
First-degree relatives, especially siblings, are at greatest risk,
but the risk also extends to more distant relatives [5]. Quan-
tiﬁcation of this risk depends on a combination of ethnicity,
the type of IBD-CD or ulcerative colitis, and the exact rela-
tionship between the person at risk and the proband [6]. In
CD there is concordance for disease location as well as the
type of disease among relatives [3, 7], and twin studies con-
sider a strong evidence for genetic role in the etiology of CD
[8].
The age-adjusted relative risk in most studies is based
on calculations using Stromgr¨ en’s methodology [9] ,ar i s k
assessment, based on patients living to age 70 years. These
studies give a lifetime risk of developing IBD for ﬁrst-degree
relativ esofaCDprobandof4.8–5.2%fornon-jewsand7.8%
for jews [6, 7]. Parents of children with IBD have been con-
sistently found to be the ﬁrst-degree relatives at lowest risk
of developing IBD. The age-corrected risk for parents of a
CD proband is 1.9–4.8% for non-jews and 2.2–3.8% for jews
[5, 10].
Most studies on relatives of CD patients have analyzed
intestinal permeability [10], luminal prostaglandins [11],
hyaluronin release, or cytokine levels in the normal look-
ing colonic mucosa compared to controls [12]. It was already
published that the greatest risk factor for the development of
IBD is having an aﬀected family member [5]. Therefore, we
aimed in our study to investigate the proﬁle of hematological
parameters,whichindicateanimmuneand/orinﬂammatory
active process of ﬁrst-degree relatives (FDRs), of CD patients
in order to identify healthy FDRs that might be at risk to de-
velop CD in the future.
MATERIALS AND METHODS
Participants
Three groups of participants were included in the study.
Group 1 consisted of thirty CD patients; group 2 of ninety2 Mediators of Inﬂammation
Table 1: Demographic and clinical data of Crohn’s disease, ﬁrst-degree relatives, and control.
Sex (M/F) Mean age ± SD Mean duration of Crohn’s disease Total number (N)
(years) disease (months) activity index
Crohn’s disease 21/9 24.3 ±12.15 8 .3 ±86.76 .1 ±2.53 0
First-degree relatives 45/50 31.9 ±16.59 5
Control 15/13 36.8 ±12.62 8
healthy FDR of CD patients, and group 3 of twenty-eight
normal controls. All CD patients were recruited from the
Gastroenterology Outpatient Clinic in Assaf Harofeh med-
ical Center in Israel. The inclusion criteria for group 1 were
new onset CD or known patients who stopped the 5-amino-
salycilic acid treatment one week prior to enrolment.
We excluded patients who were under immunosuppres-
sive treatment or steroids. Activity index was assessed by us-
ing the Harvey-Bradshaw activity index [13].
We excluded FDRs with known chronic inﬂammation
and those who were under anti-inﬂammatory or immuno-
suppressive treatment. Healthy controls were recruited from
the other outpatient clinics in the same medical center. This
study was approved by the ethics review committees of the
hospital, and informed consent was obtained from all partic-
ipants.
Methods
Ten mL of peripheral venous blood were drawn from all par-
ticipants. Five mL in EDTA tubes were used for the complete
bloodcountusingSKSinstrument,CoulterCompany,andin
the other 5mL C-reactive protein (CRP) was determined by
using Array Laser Nephelometer (Beckman Company). The
hematological parameters examined were white blood count
(WBC),hemoglobin(Hb),polymorphonuclearcells(PMN),
lymphocytes (Ly), monocytes (MO), and platelets (PLT).
Statisticalanalysis
A two-tail unpaired Student t test was used to compare be-
tween each of the parameters of the diﬀerent groups. P value
<. 05 was considered as statistically signiﬁcant.
RESULTS
Demographic and clinical data are summarized in Table 1.
CD patients were younger compared to FDRs and controls:
mean ages of 24±12.1, 31.9±16.5, and 36.8±12.6 years, re-
spectively. Mean duration of disease was 58.3 ± 86.2 months
with a mean activity index of 6.1 ±2.5 (active disease is con-
sidered when score > 5). All the seven examined inﬂamma-
tory hematological parameters in the blood were found to be
signiﬁcantly diﬀerent in group 1 (CD) population compared
to group 3 (controls). In CD patients CRP, WBC, PMN, MO,
andPLTlevelswerehigherwhileHbandLylevelswerefound
to be lower. A comparison between the same hematological
parameters in groups 1 and 2 (CD versus FDRs), revealed
similarsigniﬁcantdiﬀerences,exceptfortheWBCcount.Yet,
it is important to note that the parameters of the FDR group
were between the control values and the CD patient values
(Table 2).
We identiﬁed a group of ten FDRs with a mean age of
32.8 ± 13.2 years, who were classiﬁed as high-risk relatives
(HRRs). In those relatives at least three parameters out of
the seven were signiﬁcantly diﬀerent from the normal levels
and similar to those in CD patients (Table 2). CRP and PLT
counts were the leading parameters (P<. 001 and .002), re-
spectively, followed by Hb (P<. 03). However, all the other
parameters behaved in the same manner showing a trend to-
wards the CD patients values between the values of groups 1
and 3, despite not reaching a statistical signiﬁcance (Table 2).
DISCUSSION
DespitetherecentidentiﬁcationofCard15(NOD2)asaspe-
ciﬁc susceptibility gene [10, 14, 15] for CD, the increased
risk to relatives is diﬃcult to quantify with precision [6]. We
aimed in our study to investigate the proﬁle of the routinely
examined hematological parameters of FDRs of CD patients
compared to CD patients and controls. An increase in these
parameters might indicate an active inﬂammatory process,
and therefore may be utilized as a simpler routine tool that
will enable us to detect those FDRs who might have an in-
creased risk to develop CD at the future. Our hypothesis is
based on the established evidence that in CD patients there
is an uncontrolled activation of the immune system, with
a proinﬂammatory Th1 cytokines predominant expression
[16, 17, 31]. We found seven parameters out of the nine ex-
amined (CRP, Hb, WBC, PMN, Ly, Mo, and PLT) that were
signiﬁcantly diﬀerent between CD patients and controls, but
not from FDRs. Based on these results, we identiﬁed ten
FDRs who had at least three out of the seven hematologi-
cal parameters which deviate from the normal controls by
±1 SD. We categorized them as HRR. The three parame-
ters are of inﬂammatory type (higher CRP, PMN, and PLT).
In HRRs all the seven examined parameters tended to be
at the same trend as those of CD patients. There is a clear
correlation between CD and an increased CRP level. CRP
elevation in CD patients is associated with clinical disease
activity, endoscopic inﬂammation, severely active histologic
inﬂammation, and several other biomarkers of inﬂamma-
tion like Th1 cytokines: TNF-α and IL-1β [18–20]. Platelets
are now recognized as cells deeply involved in inﬂamma-
tion. There is compelling evidence to support their role as anBroide Efrat et al 3




Control (group 3)5 (group 2)
Relatives3 High-risk
relatives4
CRP 20.4 ±25.63 .5 ±8.31 6 .4 ±21.61 .9 ±1.6
Hb 12.2 ±1.51 3 .7 ±1.51 3 .0 ±1.51 4 .1 ±1.5
WBC (×103/μL) 8.3 ±3.27 .4 ±3.28 .3 ±2.67 .0 ±1.5
PMN (×103/μL) 5.5 ±2.64 .0 ±1.85 .3 ±1.83 .9 ±1.2
Ly (×103/μL) 1.8 ±0.62 .3 ±0.62 .0 ±0.72 .2 ±0.6
Mono (×103/μL) 0.8 ±0.30 .6 ±0.30 .7 ±0.20 .6 ±0.1
PLT (×103/μL) 315 ±92.1 226.5 ±64.2 310.1 ±111.3 214.2 ±59.3
Total number 30 85 10 28
1 All parameters of this group except for WBC count were signiﬁcantly diﬀerent (P<. 05) from the group of all ﬁrst-degree relatives.
2No diﬀerences were found between Crohn’s disease patients and high-risk relatives.
3Statistically signiﬁcant diﬀerences (P<. 05) were found between this group and high-risk relatives in the parameters of CRP, PMN, and PLT.
4Statistically signiﬁcant diﬀerences (P<. 05) were found between this group and controls in the parameters of CRP, Hb, PMN, and PLT.
5All parameters of this group were signiﬁcantly diﬀerent (P<. 05) from the group of Crohn’s disease patients.
active player in the mucosal tissue injury that occurs in CD
[21, 22]. Both CD and UC are associated with abnormalities
of platelet number and function. In the peripheral circula-
tion, the state of platelet activation is typically increased, and
IBD-involved mucosa frequently contains platelet aggregates
with mucosal microthrombi. The relevance of platelets dys-
function to IBD is still unclear, but there is solid evidence
demonstrating that platelets, in addition to their traditional
role in hemostasis, can also function as potent proinﬂamma-
tory cells [23].Uponactivation,plateletssecretealargenum-
ber of biologically active molecules able to induce or amplify
an inﬂammatory process through many of the same cellular
and molecular pathways conventionally utilized by immune
cells mediating IBD [24].
Furthermore, the prevalence of anemia in patients with
IBD ranges from 8.8% to 73.3% depending on the patient
subpopulation [25]. Thirty years ago the Crohn’s disease ac-
tivity index was established by utilizing selected variables in-
cluding the hemoglobin [26]. Since then, anemia is known
t oc o r r e l a t ew i t hC Da c t i v i t y[ 27]. Another parameter which
was increased in HRRs and was similar to the values of CD
patients was the PMN count. Active CD causes an elevation
of white blood count predominantly due to an increase in
PMN leukocytes [27]. In the literature, it was allready pub-
lished that increasd leukocyte addhesiveness/aggregation is a
most useful indicator of disease activity in patients with IBD
[28]. Phagocytosis and killing exerted by PMN were signiﬁ-
cantly reduced in CD patients [29]. In this regard, it should
be mentioned that a decreased PMN phagocytic activity was
found not only in CD patients but in their relatives com-
pared to controls [30]. In addition to the above-mentioned
inﬂammatory parameters, it was also found that in CD pa-
tients, there is an increased density and number of mononu-
clear cells in the intestinal lamina propria with an abnormal
diﬀerentiation [16]. It is known that during exacerbation of
CD,thetotalnumberoftheperipheralbloodmonocytesmay
be elevated in about 50% of the patients. Moreover, the total
peripheral monocytes count of CD patients might be higher
compared to healthy controls, as well as increased peripheral
blood macrophage activation, with an increased phagocyto-
sis and motility, spontaneous production of giant cells, su-
peroxide anion, and lysosomal enzymes secretion [17, 31].
We found as well that monocytes are increased in CD pa-
tients and in HRRs compared to the controls, but did not
reachasigniﬁcantdiﬀerence. Similar results were reported in
another study, where peripheral blood monocytes counts in
patients with inﬂammatory bowel disease were raised com-
pared with that of the control groups, but the diﬀerence did
not reach statistical signiﬁcance [32]. In addition to the con-
ventional hematological parametrs, there is also evidence for
elevated inﬂammatory cytokines in CD patients. Indaram
et al measured the levels of cytokines in the colonic mu-
cosa of asymptomatic ﬁrst-degree relatives of CD patients.
Increased levels of IL-2, IL-6, and IL-8 were found in the
colonic mucosa. It is not clear if these increased levels are
phenotyping markers for a genetic predisposition to devel-
oping CD later on, or whether they represent a preclinical
damage that has to be further deﬁned [33]. Our prelimi-
nary results show that the expression of TNF-α in periph-
eral mononuclear cells was higher in the group of 14 rela-
t i v e sa sw e l la si nC Dp a t i e n t s .U n f o rt u n a t e l y ,w ed on o th a v e
enough data regarding TNF-α mRNA expression in HRRs
due to the small population tested. Our ﬁndings in CD and
HRRs concur with previous evidence that in CD patients
thereisanincreaseinhematologicalparametersthatindicate
an inﬂammatory process. Moreover, we are the ﬁrst to show
that a certain fraction of FDRs that we termed HRRs exhibits
inﬂammatory characteristics similar to CD patients, despite
being symptom-free. Thus we suggest a more simple as well
aslessmoney-consumingtooltoselectFDRswithaprobable
increased risk to develop the disease. We believe that further
prospective studies will illuminate this important issue.4 Mediators of Inﬂammation
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